Scholarlink

<p>Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent subcutaneous and/or submucosal edema, most commonly caused by deficiency in C1-esterase inhibitor. There has been a paradigm shift in treatment goals—from merely managing acute attacks to improving or normalizing quality of life, thanks to the availability and accessibility of modern, HAE-specific medications. However, for a large majority of countries in the world, HAE-specific medications are still not available or accessible. The correspondence on ‘The International/Canadian Hereditary Angioedema Guideline’ tries to address global disparities in HAE care, highlight the key challenges in low- and middle-income countries and provide potentially viable and equitable solution to address disparities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From guidelines to global impact: updates to address disparities in hereditary angioedema care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Ankur Kumar Jindal,
  • Philip H. Li

摘要

Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent subcutaneous and/or submucosal edema, most commonly caused by deficiency in C1-esterase inhibitor. There has been a paradigm shift in treatment goals—from merely managing acute attacks to improving or normalizing quality of life, thanks to the availability and accessibility of modern, HAE-specific medications. However, for a large majority of countries in the world, HAE-specific medications are still not available or accessible. The correspondence on ‘The International/Canadian Hereditary Angioedema Guideline’ tries to address global disparities in HAE care, highlight the key challenges in low- and middle-income countries and provide potentially viable and equitable solution to address disparities.